02.06.2013 Views

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

380 MYCOPHENOLATE<br />

(2005): Prokopenko EI+, Ter Arkh 77(1), 67<br />

(2005): Shipkova M+, Expert Opin <strong>Drug</strong> Metab Toxicol 1(3), 505<br />

(2002): Bernabeu-Wittel M+, Eur J Clin Microbiol Infect Dis<br />

21(3), 173<br />

Myalgia/Myositis/Myopathy/Myotoxicity<br />

(2005): Galindo M+, J Rheumatol 32(1), 188<br />

(2005): Shipkova M+, Expert Opin <strong>Drug</strong> Metab Toxicol 1(3), 505<br />

(2002): Greiner K+, Ophthalmologe 99(9), 691<br />

Thrombophlebitis (1–10%)<br />

MYRRH<br />

Scientific names: Commiphora abyssinica; Commiphora erythraea;<br />

Commiphora habessinica; Commiphora kataf; Commiphora<br />

madagascariensis; Commiphora molmol; Commiphora myrrh<br />

Family: Burseraceae<br />

Trade <strong>and</strong> other common names: Bal; Balsamodendron;<br />

Bdellium; Bol; Bola; Didin; Didthin; Heerabol; Mirazid; Mirra;<br />

Morr<br />

Category: Anti-inflammatory; Antihelmintic<br />

Purported indications <strong>and</strong> other uses: Fascioliasis,<br />

schistosomiasis, ulcers, eczema, catarrh, amenorrhea, gum<br />

disease, aphthous stomatitis<br />

Half-life: N/A<br />

Clinically important, potentially hazardous interactions<br />

with: methimazole, propylthiouracil<br />

Reactions<br />

Skin<br />

Dermatitis<br />

(2000): Anderson C+, Phytother Res 14(6), 452<br />

(1999): Gallo R+, Contact Dermatitis 41(4), 230<br />

(1998): Al-Suwaidan SN+, Contact Dermatitis 39(3), 137<br />

(1993): Lee TY+, Contact Dermatitis 28(2), 89<br />

(1993): Lee TY+, Contact Dermatitis 29(5), 279<br />

Pruritus (0.5%)<br />

(2001): Sheir Z+, Am J Trop Med Hyg 65(6), 700 (0.5%)<br />

Side effects (sic)<br />

(2001): Sheir Z+, Am J Trop Med Hyg 65(6), 700 (mild &<br />

transient)<br />

Other<br />

Abdominal pain (2%)<br />

(2001): Sheir Z+, Am J Trop Med Hyg 65(6), 700 (2%)<br />

Rhabdomyolysis<br />

(2004): Bianchi A+, Ann Pharmacother 38(7-8), 1222<br />

NABILONE<br />

Trade name: Cesamet (Valeant)<br />

Indications: Nausea <strong>and</strong> vomiting<br />

Category: Cannabinoid<br />

Half-life: ~2 hours<br />

Clinically important, potentially hazardous interactions<br />

with: CNS depressants<br />

Reactions<br />

Mucosal<br />

Xerostomia<br />

(2006): Berlach DM+, Pain Med 7(1), 25<br />

(1986): Pomeroy M+, Cancer Chemother Pharmacol 17(3), 285<br />

(1983): George M+, Biomed Pharmacother 37(1), 24<br />

Eyes<br />

Vision blurred<br />

(1985): Ward A+, <strong>Drug</strong>s 30(2), 127<br />

Other<br />

Abdominal pain<br />

NABUMETONE<br />

Trade names: Arthaxan; Consolan; Nabuser; Prodac; Relafen<br />

(GSK); Relif; Relifex; Unimetone<br />

Indications: Arthritis<br />

Category: Non-steroidal anti-inflammatory<br />

Half-life: 22.5–30 hours<br />

Clinically important, potentially hazardous interactions<br />

with: methotrexate<br />

Reactions<br />

Skin<br />

Acne (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!